Thursday, January 1, 2009

Novartis spent almost $1.4 million lobbying in 3Q

Swiss pharmaceutical maker Novartis AG spent nearly $1.4 million lobbying the U.S. government in the third quarter, according to a recent disclosure form.

Novartis (nyse: NVS - news - people ) lobbied on bills designed to ensure the government has a sufficient stockpile of influenza vaccine in case of an outbreak, and that the government helps pay for vaccines for seniors, children and uninsured adults. The company makes flu vaccine, as well as vaccines against rabies, meningitis and several childhood illnesses.

Novartis also lobbied on the Defense Department's budget and another bill involving the military's Tricare program, which insures about 9 million current and retired service members and dependents. The company, which makes two anti-rejection drugs, Neoral and Myfortic, lobbied to provide comprehensive coverage for immune-suppressing drugs for kidney transplant patients.


No comments: